| Name | Title | Contact Details |
|---|---|---|
Trevor Timmons |
Chief Technology Officer | Profile |
Our focus is on genetics
Lindsey Management Co., Inc. (LMC) is a leading property management firm located in Fayetteville, Arkansas. Founded in 1985, it has become the largest company in Arkansas specializing in multi-family housing and has expanded its services into neighboring states such as Alabama, Kansas, Mississippi, Missouri, and Oklahoma. LMC provides a wide range of property management services, primarily focusing on multi-family housing. The company manages over 140 apartment communities, totaling more than 32,000 apartments and executive suites. Additionally, LMC oversees numerous golf courses, including five Par 3 courses, five executive courses, thirteen regular courses, and sixteen 18-hole courses across Arkansas and surrounding states. Its services include leasing, maintenance, and customer support for both residential and recreational properties.
Swagelok is a manufacturer and supplier of gas and fluid systems components.
Marsh Furniture Company is a family-owned cabinetry manufacturer based in High Point, North Carolina, established in 1906. The company specializes in kitchen and bath cabinetry, offering a product line known as Marsh Cabinets. These cabinets feature traditional face frame construction and are available in various wood species, including Oak, Birch, Maple, and Cherry. Marsh is recognized for its durable and stylish storage solutions, catering to both residential remodels and large-scale developments. Operating from a 700,000-square-foot facility, Marsh combines traditional craftsmanship with modern innovation. The company emphasizes quality and service while maintaining strong relationships with independent kitchen and bath dealers across the eastern United States. Marsh Furniture Company is committed to the well-being of its employees and the local community, reflecting over a century of dedication to integrity and craftsmanship.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.